Alopecia

Posts

Flourish to Combat Female Hair Loss

Flourish to Combat Female Hair Loss

Virtue Labs Introduces Flourish to Combat Female Hair Loss

Virtue Labs, makers of the multi-award-winning biotech hair care brand Virtue®, announced today the launch of their new Flourish® product line specifically to target female hair loss and provide thicker, fuller, and healthier hair for all.

While traditionally considered a male problem, half of all women will suffer from hair loss in their lifetime, and 40% by the time they are 40 according to the American Academy of Dermatology.

In fact, there are an estimated 30 million women in the United States suffering from hair loss, and the numbers continue to accelerate. To address this problem, Virtue took a holistic approach in creating this new line by focusing on scalp fertility and, also importantly, on hair fiber survival, with each product in the line powered by their exclusive, groundbreaking keratin protein complex Alpha Keratin 60ku CLINICAL®.

As the scalp is the starting point for hair growth, Virtue Flourish starts there too. Flourish products create a fertile environment for hair to grow by nourishing the microbiome, clearing the follicles, and strengthening the moisture barrier. Because new hair can only survive if it is nurtured and cared for, the Alpha Keratin 60ku CLINICAL nourishes new fragile hair as it emerges, increasing the strength and thickness of each new fiber.

Independent clinical testing showed that after only five uses, Virtue Flourish with Alpha Keratin 60ku CLINICAL increased the thickness of individual hair strands by 22% and reduced hair breakage by 26%, thereby giving new hairs a better chance at survival.

“As a biotech brand born from regenerative medicine, Virtue has always gone where our technology has led us, and that is certainly true with Flourish.

After launching our initial Virtue hair care line, we kept hearing from customers that their hair was growing faster or that they thought they could see new growth. That sent us on a three-year journey of discovery to see what our technology could do if we partnered it with other ingredients specifically to address this crucial problem,” said Melisse Shaban, Founder & CEO of Virtue Labs. “Hair loss is a silent epidemic that women are facing alone. With this launch, we aim to provide truly efficacious products and to shatter the stigma of women’s hair loss with open conversation around this important topic.”

Virtue’s Flourish line features six products that can be purchased individually or within two three-step regimens. The Flourish Nightly Intensive Hair Growth Treatment Regimen ($134) is a three-month regimen for moderate to severe hair thinning and contains Minoxidil, the only single ingredient FDA-approved to help regrow hair in women. The Flourish Nightly Intensive Hair Rejuvenation Treatment Regimen ($134) is a 100% drug-free alternative that features Virtue’s new Density Booster to serve mild to moderate hair thinning and those seeking a more natural approach. The Flourish lineup includes:

  • Flourish Shampoo for Thinning Hair ($42): A gentle, stimulating shampoo that delicately removes scalp buildup, cleanses the hair shaft, and clears debris from follicle openings, creating an environment for healthy growth.
  • Flourish Conditioner for Thinning Hair ($44): A lightweight conditioner that serves as a hair strengthener, hydrator, and detangler all in one. Specifically developed for fine, fragile strands, it nourishes and thickens each hair without weighing it down.
  • Flourish Density Booster ($48): A potent, botanical-based, drug-free nutrient infusion for the scalp, the Density Booster works while you sleep to fuel fatigued follicles and nurture new, fragile hairs so they thrive. For those seeking a more natural solution.
  • Flourish Volumizing Styler ($42): The all-you-need styler for fine, fragile hair, this airy, lightweight formula provides instant body, bounce, and hold, creating the illusion of density even in the thinnest parts.
  • Minoxidil 5% ($28): Used by millions, this is the only single ingredient FDA approved to help regrow hair in women. The nightly application works while you sleep to reactivate the hair follicles and stimulate regrowth.
  • Flourish x Manta Brush ($32): Virtue partnered with U.K. based Manta to offer this uniquely designed brush created specifically for fragile hair. The revolutionary Manta brush bends and molds to the shape of your hand and scalp, creating less tension on each strand. Its flexible bristles glide responsively through the hair, minimizing breakage and restoring a youthful, silky shine.

Virtue Flourish products have been tested through an independent lab on real women under real conditions, and 97% said their scalp feels healthier, 90% said they had more volume and 90% said they saw new growth*.

“Traditionally, hair loss products have been difficult to use, and often harsh on the hair, so women give up before seeing results. Virtue Flourish begins immediately to improve the health and appearance of her existing hair so that she loves the way she looks while she’s growing more,” Shaban said. “We’re excited to present this innovation to women in their search for solutions to their hair loss or thinning.”

Virtue Flourish is available for purchase on virtueflourish.com and will be available in select Bluemercury stores and on Dermstore.com starting in April 2021.

* Consumer perception results after 6 months of Virtue Flourish® Regimen use. Hair growth was seen to be healthier.

+++

About Virtue Labs:

Virtue Labs manufactures and markets innovative, technology-based solutions for the health of hair that provide visible, transformational results. Its proprietary, patented hero ingredient, Alpha Keratin 60ku®, is keratin in its purest, native form – whole, unbroken and fully functional. It is the only fully functional, human-identical keratin protein on the market today, and it is found in each of the company’s Virtue® haircare products. Virtue Labs is based in Raleigh, NC, with a technology manufacturing facility in Winston-Salem, NC. For more information please visit: www.virtuelabs.com.

Virtue Labs Introduces Flourish to Combat Female Hair Loss

Source

Recent Posts

Flourish to Combat Female Hair Loss

Flourish to Combat Female Hair Loss

Virtue Labs Introduces Flourish to Combat Female Hair Loss

Virtue Labs, makers of the multi-award-winning biotech hair care brand Virtue®, announced today the launch of their new Flourish® product line specifically to target female hair loss and provide thicker, fuller, and healthier hair for all.

While traditionally considered a male problem, half of all women will suffer from hair loss in their lifetime, and 40% by the time they are 40 according to the American Academy of Dermatology.

In fact, there are an estimated 30 million women in the United States suffering from hair loss, and the numbers continue to accelerate. To address this problem, Virtue took a holistic approach in creating this new line by focusing on scalp fertility and, also importantly, on hair fiber survival, with each product in the line powered by their exclusive, groundbreaking keratin protein complex Alpha Keratin 60ku CLINICAL®.

As the scalp is the starting point for hair growth, Virtue Flourish starts there too. Flourish products create a fertile environment for hair to grow by nourishing the microbiome, clearing the follicles, and strengthening the moisture barrier. Because new hair can only survive if it is nurtured and cared for, the Alpha Keratin 60ku CLINICAL nourishes new fragile hair as it emerges, increasing the strength and thickness of each new fiber.

Independent clinical testing showed that after only five uses, Virtue Flourish with Alpha Keratin 60ku CLINICAL increased the thickness of individual hair strands by 22% and reduced hair breakage by 26%, thereby giving new hairs a better chance at survival.

“As a biotech brand born from regenerative medicine, Virtue has always gone where our technology has led us, and that is certainly true with Flourish.

After launching our initial Virtue hair care line, we kept hearing from customers that their hair was growing faster or that they thought they could see new growth. That sent us on a three-year journey of discovery to see what our technology could do if we partnered it with other ingredients specifically to address this crucial problem,” said Melisse Shaban, Founder & CEO of Virtue Labs. “Hair loss is a silent epidemic that women are facing alone. With this launch, we aim to provide truly efficacious products and to shatter the stigma of women’s hair loss with open conversation around this important topic.”

Virtue’s Flourish line features six products that can be purchased individually or within two three-step regimens. The Flourish Nightly Intensive Hair Growth Treatment Regimen ($134) is a three-month regimen for moderate to severe hair thinning and contains Minoxidil, the only single ingredient FDA-approved to help regrow hair in women. The Flourish Nightly Intensive Hair Rejuvenation Treatment Regimen ($134) is a 100% drug-free alternative that features Virtue’s new Density Booster to serve mild to moderate hair thinning and those seeking a more natural approach. The Flourish lineup includes:

  • Flourish Shampoo for Thinning Hair ($42): A gentle, stimulating shampoo that delicately removes scalp buildup, cleanses the hair shaft, and clears debris from follicle openings, creating an environment for healthy growth.
  • Flourish Conditioner for Thinning Hair ($44): A lightweight conditioner that serves as a hair strengthener, hydrator, and detangler all in one. Specifically developed for fine, fragile strands, it nourishes and thickens each hair without weighing it down.
  • Flourish Density Booster ($48): A potent, botanical-based, drug-free nutrient infusion for the scalp, the Density Booster works while you sleep to fuel fatigued follicles and nurture new, fragile hairs so they thrive. For those seeking a more natural solution.
  • Flourish Volumizing Styler ($42): The all-you-need styler for fine, fragile hair, this airy, lightweight formula provides instant body, bounce, and hold, creating the illusion of density even in the thinnest parts.
  • Minoxidil 5% ($28): Used by millions, this is the only single ingredient FDA approved to help regrow hair in women. The nightly application works while you sleep to reactivate the hair follicles and stimulate regrowth.
  • Flourish x Manta Brush ($32): Virtue partnered with U.K. based Manta to offer this uniquely designed brush created specifically for fragile hair. The revolutionary Manta brush bends and molds to the shape of your hand and scalp, creating less tension on each strand. Its flexible bristles glide responsively through the hair, minimizing breakage and restoring a youthful, silky shine.

Virtue Flourish products have been tested through an independent lab on real women under real conditions, and 97% said their scalp feels healthier, 90% said they had more volume and 90% said they saw new growth*.

“Traditionally, hair loss products have been difficult to use, and often harsh on the hair, so women give up before seeing results. Virtue Flourish begins immediately to improve the health and appearance of her existing hair so that she loves the way she looks while she’s growing more,” Shaban said. “We’re excited to present this innovation to women in their search for solutions to their hair loss or thinning.”

Virtue Flourish is available for purchase on virtueflourish.com and will be available in select Bluemercury stores and on Dermstore.com starting in April 2021.

* Consumer perception results after 6 months of Virtue Flourish® Regimen use. Hair growth was seen to be healthier.

+++

About Virtue Labs:

Virtue Labs manufactures and markets innovative, technology-based solutions for the health of hair that provide visible, transformational results. Its proprietary, patented hero ingredient, Alpha Keratin 60ku®, is keratin in its purest, native form – whole, unbroken and fully functional. It is the only fully functional, human-identical keratin protein on the market today, and it is found in each of the company’s Virtue® haircare products. Virtue Labs is based in Raleigh, NC, with a technology manufacturing facility in Winston-Salem, NC. For more information please visit: www.virtuelabs.com.

Virtue Labs Introduces Flourish to Combat Female Hair Loss

Source

Recent Posts

Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies

PRP and Stem cell alopecia

U.S. PRP and Stem cell alopecia treatment Market Report Overview

U.S. PRP and Stem cell alopecia treatment market garnered a revenue of USD 129.4 million in the year 2019 globally and is anticipated to reach USD 189.2 million by 2027, growing at a compound annual growth (CAGR) of 4.9% over the forecast period.

The market has been observed to be growing at a steady growth rate over the last three years, however, with the impact of the COVID-19 pandemic globally, the business conditions are expected to change. The market size may reduce significantly or increase with a spike depending on how the value chain has been affected in the entire process.

Players that are operational in the market for a longer period of time are anticipated to absorb the sudden changes, losses and increased operational costs better than those who have recently entered the market.

The report focuses on numerous factors that are anticipated to impact the market growth directly and indirectly. The report categorically analyses the growth patterns of different segments based on multiple derivation models.

Both the qualitative and quantitative aspects have been covered under the report. The U.S. PRP & Stem cell alopecia treatment market report includes market size, drivers, restraints, opportunities and trends that will help you understand the market dynamics in detail.

Moreover, the report will include market estimates & forecasts in terms of revenue for the overall market along with the segments mentioned in the study. The report focuses on providing a holistic view of the entire market scenario from multiple unmatched detailed analysis mentioned in the report.

What to expect from the report?

  • U.S. PRP and Stem cell alopecia treatment Total Available Market (TAM)Size
  • U.S. PRP and Stem cell alopecia treatment Serviceable Available Market (SAM) Size
  • Business Implications of COVID-19 on the Overall Market
  • Market Share/ Revenue Share (%) of Top Market Players in Total Market Size (2019)
  • Market Size & Forecast (2016-2027) At Country & Regional Level, By Segments
  • Overview & Analysis of Key Players Operating in the Market

Key Highlights:

COVID-19 – Impact of COVID-19 on overall business scenario

U.S. PRP and Stem cell alopecia treatment Market Revenue 2020

Global market revenue in 2020 will be derived taking into various micro & macro-level factors; along with the COVID-19 pandemic

Competitive Analysis Company Market Share Analysis, 2019 (%)

Supply Chain Analysis – Analysis pertaining to several participants of the supply chain such as raw material suppliers, distributors, & OEMs along with others will be highlighted in the study

Data Source Primary & Secondary Research, Internal DataBase & Company Annual Reports

Regions Included North America,

Countries Included U.S., Canada,

U.S. PRP and Stem cell alopecia treatment Market Report Overview

Source

Recent Posts

Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies

Stem Cell and Platelet Rich Plasma Alopecia Therapies

COVID-19 Impact on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size, Status and Forecast 2020-2026t

This report focuses on the global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study

Orange County Hair Restoration Center
Hair Sciences Center of Colorado
Anderson Center for Hair
Evolution Hair Loss Institute
Savola Aesthetic Dermatology Center
Virginia Surgical Center
Hair Transplant Institute of Miami
Colorado Surgical Center & Hair Institute

Market segment by Type, the product can be split into

Platelet Rich Plasma Injections
Stem Cell Therapy
Market segment by Application, split into
Dermatology Clinics
Hospitals

Market segment by Regions/Countries, this report covers

North America
Europe
China
Japan
Southeast Asia
India
Central & South America

The study objectives of this report are:

To analyze global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies status, future forecast, growth opportunity, key market and key players.
To present the Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by type, market and key regions.

In this study, the years considered to estimate the market size of Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies are as follows:

History Year: 2015-2019
Base Year: 2019
Estimated Year: 2020
Forecast Year 2020 to 2026

For the data information by region, company, type and application, 2019 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Summary:

Get the latest Market Research Reports on COVID-19 Impact on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies. Industry analysis & Market Report on COVID-19 Impact on Global Stem

Cell and Platelet Rich Plasma (PRP) Alopecia Therapies is a syndicated market report, published as COVID-19 Impact on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size,

Status and Forecast 2020-2026. It is a complete Research Study and Industry Analysis of COVID-19 Impact on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies market, to understand,

Market Demand, Growth, trends analysis and Factor Influencing market.

COVID-19 Impact on Global Stem Cell and Platelet Rich Plasma (PRP) Alopecia Therapies Market Size, Status and Forecast 2020-2026

Source

Recent Posts

Hair Regrowth in Phase 3 Alopecia Areata

Hair Regrowth in Phase 3 Alopecia Areata

Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial

Eli Lilly and Company announced today top-line results from BRAVE-AA2, a Phase 3 study evaluating the efficacy and safety of once-daily baricitinib 2-mg and 4-mg in adults with severe alopecia areata (AA).

Both doses of baricitinib met the primary efficacy endpoint at Week 36, demonstrating a statistically significant improvement in scalp hair regrowth compared to those randomized to placebo. AA is an autoimmune disease that causes patchy hair loss on the scalp, face and sometimes on other areas of the body that can progress.

Baricitinib has received Breakthrough Therapy designation from the U.S. Food and Drug Administration (FDA) for the treatment of AA. This classification aims to expedite the development and review of drugs that are intended to treat a serious condition when preliminary clinical evidence indicates that the drug may demonstrate substantial improvement over already available therapies on a clinically significant endpoint(s). There are currently no FDA-approved treatments for AA.

“These positive results are very promising and suggest that baricitinib has the potential to address the urgent needs of people living with alopecia areata,” said Brett King, M.D., Ph.D., associate professor of Dermatology at Yale School of Medicine. “This level of high-quality research is needed to advance our understanding and the treatment of this frequently devastating disease.”

This multicenter, randomized, double-blind, placebo-controlled study included 546 adults with a Severity of Alopecia Tool (SALT) score ≥ 50 (i.e., who had ≥50% scalp hair loss) and a current episode of severe AA lasting at least six months but no more than eight years. The study included a diverse patient population from Argentina, Australia, Brazil, China, Israel, Japan, South Korea, Taiwan and the U.S.

Safety outcomes of baricitinib in BRAVE-AA2 were consistent with its established safety profile in patients with rheumatoid arthritis (RA) and atopic dermatitis (AD). No deaths, major adverse cardiovascular events (MACE) or venous thromboembolic events (VTEs) were reported in the study.

BRAVE-AA2 is the first Phase 3 study with positive results in patients with AA. Data from an additional Phase 3 study of baricitinib in AA will be available in the first half of this year. Detailed results from the BRAVE program will be presented at an upcoming medical conference and published in a peer-reviewed journal later this year. AA is the second potential treatment indication in dermatology for baricitinib after AD.

“For patients who suffer from alopecia areata, it is not a cosmetic condition, it is a devastating autoimmune disease that can have significant psychological effects. They lose much more than just hair,” said Lotus Mallbris, M.D., Ph.D., vice president of immunology development at Lilly. “We are looking forward to sharing the totality of data from the overall clinical development program for baricitinib as a potential first-in-disease treatment for alopecia areata.”

“Significant unmet need exists in the treatment of alopecia areata,” said Abby Ellison, research director at the National Alopecia Areata Foundation (NAAF). “We appreciate Lilly’s important work in this area and are excited that these data could bring us closer to a potential new treatment option for patients.”

Baricitinib is an oral JAK inhibitor discovered by Incyte and licensed to Lilly. It is approved and commercially available as OLUMIANT in the U.S. and more than 70 countries as a treatment for adults with moderate to severe active RA and in the European Union and Japan for the treatment of adult patients with moderate to severe AD who are candidates for systemic therapy. Baricitinib is also being investigated in systematic lupus erythematosus (SLE), juvenile idiopathic arthritis (JIA) and COVID-19.

Baricitinib is First JAK-Inhibitor to Demonstrate Hair Regrowth in Phase 3 Alopecia Areata (AA) Trial

Source

Recent Posts

Global Alopecia Treatment Market

Speaker discusses use of JAK inhibitors in alopecia

Speaker discusses use of JAK inhibitors in alopecia

A speaker at South Beach Symposium Medical Dermatology Summit discussed the JAK inhibitors that are currently on the market and their applications in treating alopecia areata.

Antonella Tosti, MD, said that JAK inhibitors “are probably the future of treatment for alopecia areata.”

Of the three main JAK inhibitors used for alopecia areata — ruxolitinib, baricitinib and tofacitinib — tofacitinib “has been most studied,” Tosti said. The standard dose of tofacitinib is 5 mg twice daily.

Patients usually regrow hair about 3 months after beginning treatment, and even though some patients may take longer, they should “persist and continue the treatment,” she said.

About 70% of patients respond to tofacitinib, although it is typically less effective in long-standing alopecia totalis or alopecia universalis. However, the oral formulation is more effective than the topical formulation, Tosti said.

Large clinical trials for ruxolitinib and baricitinib are ongoing, according to Tosti. In the literature cited during the presentation, ruxolitinib doses were 10 mg twice daily and 10 mg every other day. She also said “usually ruxolitinib causes visible regrowth earlier than tofacitinib.”

There is not yet data on long-term side effects, but patients commonly experience upper respiratory infections, headache and weight gain. Given the potential danger of upper respiratory infections during the era of COVID-19, Tosti has advised her patients to discontinue treatment if they develop COVID-19 symptoms. Other side effects, such as severe infection, have been reported among patients taking a JAK inhibitor for another indication.

Tosti said there are several JAK inhibitor compounds in the phase 2 or 3 stage of development.

Speaker discusses use of JAK inhibitors in alopecia

Source

Recent Posts

Global Alopecia Treatment Market

Study Results for the Treatment of Androgenic Alopecia

Histogen Announces Week 26 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men

Histogen today announced week 26 results from its Phase 1b/2a clinical trial of HST-001 in male patients with androgenic alopecia. At the week 26 timepoint, patients treated with HST-001 demonstrated a statistically significant change from baseline in total hairs (terminal and vellus) in the target area (TAHC) in the vertex as measured by Canfield’s Hairmetrix macrophotography system.

HST-001 was also shown to be safe and well-tolerated at week 26 as compared to placebo with no reports of serious adverse events. Similar to the week 18 primary endpoint results we reported in December of 2020, HST-001 did not achieve statistical significance at week 26 when compared to placebo.

“The recently completed study demonstrated that HST-001 was safe, well-tolerated, and exhibited signals of efficacy. This data will inform future development, and I look forward to working with Histogen and our other expert advisors as we plan and execute the next study in men with androgenetic alopecia,” said Dr Stacy Smith, M.D., founder of the California Dermatology and Clinical Research Institution and principal investigator for the HST-001 trial.

“We are encouraged that these results demonstrated that patients treated with HST-001 grow both terminal and vellus hairs in men with androgenic alopecia,” said Richard W. Pascoe, Histogen’s President and CEO. “Moreover, 84% of the subjects who received HST-001 responded to treatment over the 26-week period and the study drug was found to be safe and well-tolerated across all subjects.

With this data in hand, we have begun planning for a more substantive clinical trial in men with androgenic alopecia with the goal of determining the best clinical pathway for future registration trials. We anticipate the trial will commence in the second half of 2021.”

About the HST-001 Phase 1a/2b Study
This 2:1 randomized, blinded, the placebo-controlled, single-site study enrolled 36 male patients with androgenic alopecia with mild to moderate hair loss on a Norwood-Hamilton (N-H) Scale (3V, 4, 5), with a total of 30 evaluable patients at week 26.

It was designed to assess the safety and tolerability of HST-001, as well as indicators of efficacy at weeks 18 and 26. The primary study endpoint is an absolute change from baseline versus week 18 in total hairs (terminal and vellus) in the (TAHC) of the vertex as measured by Canfield’s Hairmetrix macrophotography system.

Secondary endpoints include absolute change from baseline in total hairs (terminal and vellus) new terminal and vellus hair count, hair thickness density and per cent change from baseline in TAHC, terminal and vellus hair counts in the vertex and right temporal regions at weeks 18 and 26, all as measured by Canfield’s Hairmetrix macrophotography system. At each treatment time point (Weeks 0, 6 and 12), patients received a total of 20 injections, 10 in the vertex scalp region and 5 in each temporal region for a total dose of 2mL.

About HST-001
HST-001, or Hair Stimulating Complex (HSC), is intended to be a physician-administered therapeutic for hair loss. HSC is anticipated to be a relatively safe, minimally invasive treatment that promotes new hair growth where existing treatments only reduce hair loss. HSC is manufactured to enrich for growth factors including KGF, VEGF and follistatin, which are involved in signaling stem cells in the body and have been shown to be important in hair formation and the stimulation of resting hair follicles.

About Histogen
Histogen Inc. is a clinical-stage therapeutics company focused on developing potential first-in-class restorative therapeutics that ignite the body’s natural process to repair and maintain healthy biological function.

Histogen’s innovative technology platform utilizes cell conditioned media and extracellular matrix materials produced by hypoxia-induced multipotent cells. Histogen’s proprietary, reproducible manufacturing process provides targeted solutions across a broad range of therapeutic indications including hair growth, dermal rejuvenation, joint cartilage regeneration and spinal disk repair.

For more information, please visit www.histogen.com.

Histogen Announces Week 26 HST-001 Study Results for the Treatment of Androgenic Alopecia in Men

Source

Recent Posts

Preclinical Study of Hair Loss Therapeutic Candidate

Preclinical Study of Hair Loss Therapeutic Candidate

OliX Pharmaceuticals Announces Results from Preclinical Study of Hair Loss Therapeutic Candidate

OliX Pharmaceuticals, Inc, a leading developer of RNAi therapeutics, announced that it has demonstrated efficacy in a preclinical study of OLX104C, an investigational RNAi therapeutic in development for androgenic alopecia, also known as hair loss.

In the study, OLX104C was administered topically to a mouse model with suppressed hair growth (Dihydrotestosterone, DHT administered mouse). The study evaluated the percentage of hair regrowth and duration of knockdown of the target protein, AR, following a single injection.

Mice receiving OLX104C showed substantial hair regrowth compared to the control group, and results showed that a single dose could inhibit the expression of the target gene for more than three weeks.

“We are advancing a novel and potentially durable approach to treating hair loss with large market potential,” said Dong Ki Lee, PhD, founder and chief executive officer of OliX Pharmaceuticals. “Due to topical administration, our investigational therapy acts directly on the affected area and is rapidly degraded upon exposure to the blood, so it’s free from major systemic side effects such as sexual dysfunction caused by conventional hair loss therapeutics.

Building on our experience evaluating RNAi therapeutics for skin diseases, we plan to initiate clinical trials of OLX104C by 2022.”

According to Inkwood Research, the global hair loss treatment market size is estimated to grow 5.51% annually from $8.4 billion in 2018 to $13.6 billion in 2027.1

Furthermore, OliX has completed patent applications in major global markets, including the United States, Europe, Korea, and Japan, to secure exclusive rights for its hair loss treatment substance.

Dr Lee will discuss the preclinical results of OLX104C and present a corporate overview at SMi’s 12th Annual RNA Therapeutics Virtual Conference on February 11, 2021, at 9:40 a.m. GMT.

About OliX Pharmaceuticals

OliX Pharmaceuticals is a clinical-stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating expression of disease-causing genes, based on its own proprietary RNAi technology. The Company’s core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference (RNAi), which is considered as the most efficient gene silencing technology.

Based on asiRNA technology, OliX has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform to effectively target locally administrable diseases, such as hypertrophic scar, dry and wet age-related macular degeneration (AMD), subretinal fibrosis, idiopathic pulmonary fibrosis (IPF), and neuropathic pain.

OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases.

To learn more about the company, visit https://www.olixpharma.com/eng/

1 Inkwood Research. Global Alopecia (Hair Loss) Treatment Market Forecast 2019-2027. Available at: https://www.inkwoodresearch.com/reports/global-alopecia-hair-loss-treatment-market/. Accessed February 9, 2021.

OliX Pharmaceuticals Announces Results from Preclinical Study of Hair Loss Therapeutic Candidate

Source

Recent Posts

Global Alopecia Treatment Market

Global Alopecia Treatment

Market Research Report 2021-2027

The Global Alopecia Treatment Market poised to grow from US$ XX million in 2021 to US$ XX million by 2027 at a compound annual growth rate (CAGR) of XX% during the projection period of 2021-2027.

The report states that the Alopecia Treatment market condition and market forces acting across the industry. Analysts use the most recent primary and secondary research techniques and tools to arrange comprehensive and accurate marketing research reports. The research study also includes other types of analysis such as qualitative and quantitative.

All proportion of shares and breakdowns are determined using secondary sources and verified primary sources. The report could be a collection of first-hand info, qualitative and quantitative assessment by industry analysts, and industry participants across the value chain.

COVID-19 Impact Evaluation

This report also analyses the impact of Coronavirus COVID-19 on the Xxx industry.

Based on our recent survey, we have several different scenarios about the Xxx YoY growth rate for 2020. The probable scenario is expected to grow by a xx% in 2020 and the revenue will be xx in 2020 from US$ xx million in 2019. The market size of Xxx will reach xx in 2026, with a CAGR of xx% from 2021 to 2027.

Market Dynamics:

The research report provides analysis and information according to market segments such as geographies, product type, application, and end-use industry. Featuring worldwide and over leading key player profiles, this report serves the ultimate guide to exploring opportunities in the Alopecia Treatment industry globally.

The Alopecia Treatment market report provides effective guidelines and strategies for industry players to secure a position at the top in the worldwide Alopecia Treatment market. Our experts have added large key companies who play an important role in the sales, and distribution of the products. The significant applications and potential business arenas are also added to this report. It encourages the client to make strategic moves and create their businesses.

Moreover, the Alopecia Treatment market report includes information on major product categories, their demand, supply, developments, recent product approvals regulatory scenario and competitive intelligence. The regional scope of the report covers major geographical market places; North America, Europe, Asia-Pacific, Latin America and the Middle East along with market numbers, and growth potential in form of forecast market values in US$ million. Furthermore, the report also sheds light on the competitive landscape in the industry, talking about the key industry participants, their products and services, strategies, financial information and their positions in the market.

The Alopecia Treatment market report covers the following key industry participants:

Teva Pharmaceutical Industries
Merck
Johnson&Johnson
Reddy’s Laboratories
Cipla
Cellmid
Himalaya Drug
Taisho Pharmaceutical Holdings

The Alopecia Treatment Market is divided into product, application and regional market.

The product segment of the report offers product market information such as demand, supply and market value of the product.

The application of the product in terms of US$ value is represented in numerical and graphical format for all the major regional markets.

The Alopecia Treatment market report is segmented into Type by the following categories;

Topical Drugs
Oral Drugs
Injectable
Hair Transplant Services
Other

The Alopecia Treatment market report is segmented into Application by following categories;

Hospitals
Dermatology And Trichology Clinics
Home Care Settings
Other

Above information is further split with respect to following geographies;

North America
U.S.
Canada
Mexico
Europe
Germany
France
UK
Italy
Spain
Russia
Asia Pacific
China
Japan
India
South Korea
Australia
Middle East and Africa
Saudi Arabia
UAE
South Africa
South America
Brazil
Argentina

Key Information and data offered by the Alopecia Treatment market report:

Market definition, scope and assumptions

Market drivers, restraints, opportunity and challenges

Product market value and future projections in US$ million

Tabular and graphical representation of numbers and growth trend

Alopecia Treatment market estimated in terms of the market size in US$ million and forecast for product, application and regional market

The growth potential and forecast information for Global Alopecia Treatment Market and for segments, by region and by country.

The report includes competitive analysis of the Alopecia Treatment market comprising of key industry players profile. The company profiles offer company overview, business summary, product information, recent development and strategic outlook.

Global Alopecia Treatment Market Research Report 2021-2027

Source

Recent Posts

Global Alopecia Treatment Market

Global Alopecia Treatment Market

Global Alopecia Treatment Market

The Alopecia Treatment market is expected to grow in the future due to a rising R&D activity to improve treatment options and accelerated regulatory approvals.

There are five major kinds of alopecia to be specific such as androgenic alopecia, alopecia areata, alopecia totalis, cicatricial alopecia, and telogen effluvium.

The rising prevalence of chronic diseases, such as acute stress disorder, Polycystic Ovary Disease (PCOD), hyperthyroidism, hypothyroidism, cancer, lupus, and hypopituitarism across the globe, is expected to augment the revenue growth over the forecast period.

Growth Drivers

  • Surge in Geriatric Population
  • Rise in Prevalence of Alopecia Conditions such as Androgenic Alopecia, Alopecia Areata, Alopecia Totalis, and Others
  • Increase in Prevalence of Chemotherapy-Induced Alopecia

Market Trends

  • Technological Advancements and the Development of Novel Therapeutic Drugs

Roadblocks

  • Lack of Reimbursement Policies
  • High Cost of Medications

Opportunities

  • Surge in Patient Awareness Regarding the Alopecia Totalis Disorder
  • Large Presence of Pharmaceutical Companies

Challenges

  • Side Effects, Reactions, and Allergies Caused by Alopecia Treatments

Competitive Landscape:

The global Alopecia Treatment market is witnessing a rise in competitiveness among the players. In terms of market share, the major players are currently dominating. However, some of the companies are increasing the market presence by securing new contracts and tapping new markets.

Some of the key players profiled in the report are Johnson & JohnsonServices, Inc. (United States), Sun Pharmaceutical Industries Ltd (India), Cipla Inc. (India), Lexington International LLC (United States), Merck & Co., Inc. (United States), Vita-Cos-Med Klett-Loch GmbH (Germany), Cirrus Hair Centers (United States), Transitions Hair Pty Ltd. (United States), Capillus (United States) and Follica, Inc. (United States). Analyst at AMA Research see United States Players to retain maximum share of Global Alopecia Treatment market by 2025.

Considering Market by Drug, the sub-segment i.e. Minoxidil will boost the Alopecia Treatment market. Considering Market by Sales Channel, the sub-segment i.e. Prescriptions will boost the Alopecia Treatment market. Considering Market by End User, the sub-segment i.e. Hospitals will boost the Alopecia Treatment market.

Latest Market Insights:

In Mar 2020, Eli Lilly and Company and Incyte Corporation announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to baricitinib for the treatment of alopecia areata (AA), an autoimmune disorder that can cause unpredictable hair loss on the scalp, face and other areas of the body.

In June 2020, Follica, Inc. announced positive feedback from a meeting with the U.S. Food and Drug Administration (FDA) as the company prepares to advance its lead program into Phase 3 development following a successful safety and efficacy optimization study for the treatment of hair loss in male androgenetic alopecia announced in December 2019., and In Oct 2020, Histogen Inc. announced the completion of patient dosing in its Phase 1b/2a clinical trial of HST-001, designed to assess the safety, tolerability, and indicators of efficacy of HST-001 for the treatment of androgenic alopecia in men.

Global Alopecia Treatment Market

Source

Recent Posts

Global Alopecia Treatment Market

Global Alopecia Treatment Market

Global Alopecia Treatment Market

Market Analysis and Insights of Global Alopecia Treatment (Hair Loss) Market

Alopecia treatment (hair loss) market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses the alopecia treatment (hair loss) market to account to USD 5,461.35 million by 2028 growing at a CAGR of 6.0% in the above-mentioned forecast period.

Rising prevalence of alopecia (hair loss) globally and extensive research & development activity in alopecia treatment (hair loss) has been directly impacting the growth of alopecia treatment (hair loss) market.

Alopecia is a condition that causes hair to fall out in small patches, which can be unnoticeable. These patches may connect, however, and then become noticeable. The condition develops when the immune system attacks the hair follicles, resulting in hair loss.

The increasing need for an effective treatment for alopecia (hair loss) is the main driving factor for the alopecia treatment (hair loss) market. Rising pharmaceutical industries and various research & clinical studies are driving the alopecia treatment (hair loss) market. Various innovative clinical programmes is an opportunity for the alopecia treatment (hair loss) market.

Lack of awareness in rural countries is a big challenge for the alopecia treatment (hair loss) market. However, the high cost of treatment is the main restraint in the growth of alopecia treatment (hair loss) market during the forecast period of 2021-2028.

This alopecia treatment (hair loss) market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, the impact of domestic and localised market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market.

In March 2018, Johnson & Johnson Services, Inc. teamed up with JW Pharmaceutical to improve the sales of its product which is Rogaine, a hair loss treatment including minoxidil. JW Pharmaceutical has signed a distributorship agreement with J&J in November 2017. Rogaine is FDA approved hair loss treatment and is considered a top-selling hair loss treatment. This lead enabled the company to gain more product sales which have increased the company’s overall revenue.

Alopecia Treatment (Hair Loss) Market Scope and Market Size

Alopecia treatment (hair loss) market is segmented on the basis of disease type, treatment, gender, form, end-user and distribution channel. The growth amongst these segments will help you analyse meagre growth segments in the industries, and provide the users with a valuable market overview and market insights to help them in making strategic decisions for identification of core market applications.

  • Based on disease type, the alopecia treatment (hair loss) market is segmented into non‒cicatricial alopecia, cicatricial alopecia, traction alopecia and others.
  • Based on treatment, the alopecia treatment (hair loss) market is segmented into localized therapies, systemic therapies, medical devices and herbal treatment.
  • Based on gender, the alopecia treatment (hair loss) market is segmented into male and female.
  • Based on form, the alopecia treatment (hair loss) market is segmented into oral, topical and parenteral.
  • Based on end-user, the alopecia treatment (hair loss) market is segmented into hospitals, home healthcare and dermatology centres.
  • Based distribution channel, the alopecia treatment (hair loss) market is segmented into direct tender, retail sales and pharmacies.

Alopecia Treatment (Hair Loss) Market Country Level Analysis

Alopecia treatment (hair loss) market is segmented into is analysed and market size insights and trends are provided by country, disease type, treatment, gender, form, end-user and distribution channel as referenced above.

The countries covered in the alopecia treatment (hair loss) market is segmented into the report are the U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of the Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America.

North America is likely to lead the alopecia treatment (hair loss) market. The regional market has been driven by a common form of alopecia and people with alopecia aerate affects. However, the growing market with new players is the main factor propelling the growth of the regional market. The market in Asia-Pacific is expected to exhibit a substantial growth rate during the forecast period 2021-2028 due to the rise in prevalence of alopecia and rising usage of hair care therapies for the treatment.

The country section of the alopecia treatment (hair loss) market is segmented into report also provides individual market impacting factors and changes in regulation in the market domestically that impact the current and future trends of the market. Data points such as consumption volumes, production sites and volumes, import-export analysis, price trend analysis, cost of raw materials, downstream and upstream value chain analysis are some of the major pointers used to forecast the market scenario for individual countries. Also, presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, the impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.

Healthcare Infrastructure Growth Installed Base and New Technology Penetration

Alopecia treatment (hair loss) market also provides you with detailed market analysis for every country growth in healthcare expenditure for capital equipment’s, installed base of different kind of products for alopecia treatment (hair loss) market, the impact of technology using lifeline curves and changes in healthcare regulatory scenarios and their impact on the alopecia treatment (hair loss) market. The data is available for the historic period 2010 to 2019.

Competitive Landscape and Alopecia Treatment (Hair Loss) Market Share Analysis

Alopecia treatment (hair loss) market competitive landscape provides details by a competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies’ focus related to alopecia treatment (hair loss) market.

The major players covered in the alopecia treatment (hair loss) market report are Alès Groupe, Gerolymatos International SA, iGrow Laser, Lexington Intl., LLC., Curallux, LLC., Follicum AB, HCell Inc., Freedom Laser Therapy, Inc., Taisho Pharmaceutical Holdings Co., Ltd., Vita-Cos-Med Klett-Loch GmbH, Vitabiotics Ltd., WOCKHARDT, Teva Pharmaceuticals USA, Inc., Pfizer Inc., Par Pharmaceutical, GlaxoSmithKline plc, Dr. Reddy’s Laboratories Ltd., Abbott, Zydus Pharmaceuticals, Inc., Johnson & Johnson Services, Inc., Cipla Inc., Sun Pharmaceutical Industries Ltd., Merck Sharp & Dohme Corp., Aurobindo Pharma, Perrigo Company plc, Viviscal Limited, Dr. Kurt Wolff GmbH & Co. KG, Nanogen, Labo International S.r.l., Watermans, WON TECH Co., Ltd., PureTech are among other domestic and global players. Market share data is available for Global, North America, Europe, Asia-Pacific (APAC), Middle East and Africa (MEA) and South America separately. DBMR analysts understand competitive strengths and provide competitive analysis for each competitor separately.

Global Alopecia Treatment Market

Source

Recent Posts